Genmab A+s

Genmab B.v.

Msd International Gmbh

Sandra Verploegen

Paul Parren

Jan Van De Winkel

David Satijn

Rob N De Jong

Patrick Van Berkel

Esther C W Breij

Willem Karel Bleeker

Steen Lisby

Reshma Abdulla Rangwala

Oyewale O Abidoye

Leonardo Viana Nicacio

Janine Schuurman

Ole Baadsgaard

Tom Vink

David P E Satijn

Eva Ehrnrooth

Mischa Houtkamp

Maroeska Oudshoorn

Vibeke Miller Breinholt

Wim Bleeker

Edward Norbert Van Den Brink

Aran Frank Labrijn

Rik Rademaker

Rene Hoet

Isil Altintas

Frank Beurskens

Esther Breij

Marije Overdijk

Shyra Gardai

Patrick Engelberts

Riemke Van Dijkhuizen Radersma

Anthony Cao

Arjen Vlug

Riemke Van Dijkhuizen

Rene M A Hoet

Rene M Hoet

David P Satijn

Rene MA Hoet

The invention provides an anti-VEGF antibody (e.g., bevacizumab) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such cervical cancer. The invention also provides compositions and kits comprising the anti-VEGF antibody (e.g., bevacizumab) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as cervical cancer.

Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate

The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate

The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder cancer and cervical cancer. The invention also provides compositions and kits comprising the platinum-based agent (e.g., carboplatin) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as bladder cancer and cervical cancer.

Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate

The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

Dimeric protein with triple mutations

Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.

Bispecific antibodies against CD3 and CD20

Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

Human antibodies against tissue factor and methods of use thereof

Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.

Human antibodies and antibody-drug conjugates against CD74

Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.

Human antibody drug conjugates against tissue factor

Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

Growing community of inventors

Utrecht, Netherlands

Sandra Verploegen